Your browser doesn't support javascript.
loading
In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019.
Karlowsky, James A; Kazmierczak, Krystyna M; Valente, Maria Lavínea Novis de Figueiredo; Luengas, Elkin Lemos; Baudrit, Monique; Quintana, Alvaro; Irani, Paurus; Stone, Gregory G; Sahm, Daniel F.
Afiliação
  • Karlowsky JA; University of Manitoba, Max Rady College of Medicine, Department of Medical Microbiology and Infectious Diseases, Winnipeg, Canada.
  • Kazmierczak KM; IHMA, Schaumburg, IL, USA. Electronic address: kkazmierczak@ihmainc.com.
  • Valente MLNF; Pfizer Brazil, São Paulo, SP, Brazil.
  • Luengas EL; Pfizer Colombia, Bogota, Colombia.
  • Baudrit M; Pfizer Central America and Caribbean, Cartago, Costa Rica.
  • Quintana A; Pfizer Inc., New York, NY, USA.
  • Irani P; Pfizer UK ltd, Walton Oaks, Tadworth, Surrey, UK.
  • Stone GG; Pfizer Inc., Groton, CT, USA.
  • Sahm DF; IHMA, Schaumburg, IL, USA.
Braz J Infect Dis ; 25(6): 101647, 2021.
Article em En | MEDLINE | ID: mdl-34774471
The Antimicrobial Testing Leadership and Surveillance (ATLAS) global surveillance program collected clinical isolates of Enterobacterales (n = 8416) and Pseudomonas aeruginosa (n = 2521) from 41 medical centers in 10 Latin American countries from 2017 to 2019. In vitro activities of ceftazidime-avibactam and comparators were determined using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method. Overall, 98.1% of Enterobacterales and 86.9% of P. aeruginosa isolates were susceptible to ceftazidime-avibactam. When isolates were analyzed by country of origin, susceptibility to ceftazidime-avibactam for Enterobacterales ranged from 97.8% to 100% for nine of 10 countries (except Guatemala, 86.3% susceptible) and from 75.9% to 98.4% for P. aeruginosa in all 10 countries. For Enterobacterales, 100% of AmpC-positive, ESBL- and AmpC-positive, GES-type carbapenemase-positive, and OXA-48-like-positive isolates were ceftazidime-avibactam-susceptible as were 99.8%, 91.8%, and 74.7% of ESBL-positive, multidrug-resistant (MDR), and meropenem-nonsusceptible isolates. Among meropenem-nonsusceptible isolates of Enterobacterales, 24.4% (139/570) carried a metallo-ß-lactamase (MBL); 83.3% of the remaining meropenem-nonsusceptible isolates carried another class of carbapenemase and 99.4% of those isolates were ceftazidime-avibactam-susceptible. Among meropenem-non-susceptible isolates of P. aeruginosa (n = 835), 25.6% carried MBLs; no acquired ß-lactamase was identified in the majority of isolates (64.8%; 87.2% of those isolates were ceftazidime-avibactam-susceptible). Overall, clinical isolates of Enterobacterales collected in Latin America from 2017 to 2019 were highly susceptible to ceftazidime-avibactam, including isolates carrying ESBLs, AmpCs, and KPCs. Country-specific variation in susceptibility to ceftazidime-avibactam was more common among isolates of P. aeruginosa than Enterobacterales. The frequency of MBL-producers among Enterobacterales from Latin America was low (1.7% of all isolates; 146/8,416), but higher than reported in previous surveillance studies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pseudomonas aeruginosa / Ceftazidima / Enterobacteriaceae / Compostos Azabicíclicos / Antibacterianos Tipo de estudo: Guideline / Screening_studies Limite: Humans Idioma: En Revista: Braz J Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá País de publicação: Brasil

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pseudomonas aeruginosa / Ceftazidima / Enterobacteriaceae / Compostos Azabicíclicos / Antibacterianos Tipo de estudo: Guideline / Screening_studies Limite: Humans Idioma: En Revista: Braz J Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá País de publicação: Brasil